LUXTURNA

Spark Therapeutics, Inc.🇺🇸 United States

FDA Page

Effective Date: Jun 22, 2022
Approval ID: 08313a24-e7ce-457a-bb3f-161bc45517ee
Products: 1 registered
Version: 10

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use LUXTURNA safely and effectively. See full prescribing information for LUXTURNA.LUXTURNA (voretigene neparvovec-rzyl) intraocular suspension for subretinal injectionInitial U.S. Approval: 2017

Quick Stats

Total Products1

Labelers2

Label Sections32

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.